background image
''
``
It is a marvelous
opportunity to
do research that
is applied in an
important way
-- Dr. Vett Lloyd
then passing the newly formed drug to the
Lloyd cell culture lab, which will expose
cancer cells to it and see if it works as ef-
ficiently as the cancer drug did on its own.
"We expect from what we know to see a
great activity, but expecting is not the same
as knowing," Stewart says.
As soon as Westcott has passed one drug
on to Lloyd, he will begin work on link-
ing another in order to test as many cancer
drugs as possible in the time they have.
The formal target is to test two drugs.
"But I think we can do better than that,"
Lloyd says.
"Absolutely," Westcott adds. "The more
you get into it, the more you want to get
into it. We want to do as many as we can."
If the new drugs work on human cancer
cells as they should, Soricimed President
and CEO Paul Gunn says they can move
on to trials in mice.
"If it had a positive effect in a mouse by the
end of the year, we could be doing human
trials within two years," he says.
The process can be used in 80 per cent of all
cancers, including breast, kidney, lung, and
ovarian, making its impact tremendous.
"It is a marvelous opportunity to do
research that is applied in an important
way," Lloyd says. "This is a very exciting
project for the Mount A cell culture lab."
/ 11
on the horizon
chance to be part of game-changing research
(L-R) Paul Gunn, Dr. Vett Lloyd, Jack Stewart,
Dr. Stephen Westcott